Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Triple Gene-Modified iPSC-Derived NK Cells Combined with Daratumumab for Targeted Immunotherapy Against AML

Frank Cichocki, PhD, Ryan Bjordahl, PhD, Karrune Woan, MD PhD, Zachary Davis, PhD BS, Greg Bonello, Sajid Mahmood, PhD, Paul Rogers, PhD, Moyar Q. Ge, PhD, Tom Lee, PhD, Martin Felices, PhD, Bruce Walcheck, PhD, Bruce R. Blazar, MD, Bahram Valamehr, PhD, Jeffrey S. Miller, MD

Blood (2020) 136 (Supplement 1): 57–58.

https://doi.org/10.1182/blood-2020-137138

Published: 2020

Journal Articles

FT576: Multi-Specific Off-the-Shelf CAR-NK Cell Therapy Engineered for Enhanced Persistence, Avoidance of Self-Fratricide and Optimized Mab Combination Therapy to Prevent Antigenic Escape and Elicit a Deep and Durable Response in Multiple Myeloma

Jode P Goodridge, PhD, Ryan Bjordahl, PhD, Sajid Mahmood, PhD, John Reiser, PhD, Svetlana Gaidarova, MS, Robert Blum, MS, Frank Cichocki, PhD, Hui-yi Chu, PhD, Greg Bonello, PhD, Tom Lee, PhD, Brian Groff, Miguel Meza, BS, Yu-Waye Chu, MD, Bruce Walcheck, PhD, Karl-Johan Malmberg, MD PhD, Jeffrey S. Miller, MD, Armin Rehm, Uta Hopken, Bahram Valamehr, PhD

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-142750

Published: 2020

Journal Articles

CAR19 iPSC-Derived NK Cells Utilize the Innate Functional Potential Mediated through NKG2A-Driven Education and Override the HLA-E Check Point to Effectively Target B Cell Lymphoma

Blood (2020) 136 (Supplement 1): 34–35.

https://doi.org/10.1182/blood-2020-138527

Published: 2020

Journal Articles

iPSC-Derived NK Cells Synergize with T Cells and Anti-PD-1 Antibody to Mediate Durable Anti-Tumor Responses In Vivo

Jeffrey S. Miller, MD, Ryan Bjordahl, PhD, Svetlana Gaidarova, MS, Sajid Mahmood, PhD, Paul Rogers, PhD, Ge Moyar, Bruce R. Blazar, MD, Dan S Kaufman, MD PhD, Bahram Valamehr, PhD, Frank Cichocki, PhD

Blood (2019) 134 (Supplement_1): 1933.

https://doi.org/10.1182/blood-2019-124961

Published: 2019

Journal Articles

FT538: Preclinical Development of an Off-the-Shelf Adoptive NK Cell Immunotherapy with Targeted Disruption of CD38 to Prevent Anti-CD38 Antibody-Mediated Fratricide and Enhance ADCC in Multiple Myeloma When Combined with Daratumumab

Ryan Bjordahl, PhD, Svetlana Gaidarova, MS, Karrune Woan, MD PhD, Frank Cichocki, PhD, Greg Bonello, PhD, Megan Robinson, Chelsea Ruller, Mochtar Pribadi, PhD, Jason Dinella, PhD, Lauren Fong, PhD, Janel Huffman, MS, Hui-yi Chu, PhD, Tom Lee, PhD, Ramzey Abujarour, PhD, Dan S Kaufman, MD PhD, Karl-Johan Malmberg, MD PhD, Jeffrey S. Miller, MD, Bahram Valamehr, PhD

Blood (2019) 134 (Supplement_1): 133.

https://doi.org/10.1182/blood-2019-131138

Published: 2019

Journal Articles

FT596: Translation of First-of-Kind Multi-Antigen Targeted Off-the-Shelf CAR-NK Cell with Engineered Persistence for the Treatment of B Cell Malignancies

Jode P Goodridge, PhD, Sajid Mahmood, PhD, Huang Zhu, PhD, Svetlana Gaidarova, MS, Robert Blum, Ryan Bjordahl, PhD, Frank Cichocki, PhD, Hui-yi Chu, PhD, Greg Bonello, PhD, Tom Lee, PhD, Brian Groff, Miguel Meza, BS, Bruce Walcheck, PhD, Karl-Johan Malmberg, MD PhD, Jeffrey S. Miller, MD, Dan S Kaufman, MD PhD, Bahram Valamehr, PhD

Blood (2019) 134 (Supplement_1): 301.

https://doi.org/10.1182/blood-2019-129319

Published: 2019

Journal Articles

NK Cells Lacking CD38 Are Resistant to Oxidative Stress-Induced Death

Frank Cichocki, PhD, Karrune Woan, MD PhD, Cheng-Ying Wu, Bruce R. Blazar, MD, Ryan Bjordahl, PhD, Bahram Valamehr, PhD, Jeffrey S. Miller, MD

Blood (2019) 134 (Supplement_1): 3215.

https://doi.org/10.1182/blood-2019-124490

Published: 2019

Journal Articles

CD38-Deficient, CD16-Engineered NK Cells Exhibit Enhanced Antibody-Dependent Cellular Cytotoxicity without NK Cell Fratricide to Augment Anti-Myeloma Immunity in Combination with Daratumumab

Karrune Woan, MD PhD, Ryan Bjordahl, PhD, Frank Cichocki, PhD, Svetlana Gaidarova, MS, Cameron Pride, BS, Dan S Kaufman, MD PhD, Karl-Johan Malmberg, MD PhD, Sarah Cooley, MD, Bahram Valamehr, PhD, Jeffrey S. Miller, MD

Blood (2018) 132 (Supplement 1): 3224.

https://doi.org/10.1182/blood-2018-99-116459

Published: 2018

Journal Articles

iPSC-Derived NK Cells and Anti-PD-1 Antibody Synergize to Enhance T Cell Cytokine and Cytolytic Responses Against Multiple Tumors

Frank Cichocki, PhD, Ryan Bjordahl, PhD, Svetlana Gaidarova, MS, Sajid Mahmood, PhD, Paul Rogers, PhD, Moyar Q. Ge, PhD, Dan S Kaufman, MD PhD, Sarah Cooley, MD, Bahram Valamehr, PhD, Jeffrey S. Miller, MD

Blood (2018) 132 (Supplement 1): 730.

https://doi.org/10.1182/blood-2018-99-114893

Published: 2018

Journal Articles

Off-the-Shelf Natural Killer Cells with Multi-Functional Engineering Using a Novel Anti-CD19 Chimeric Antigen Receptor Combined with Stabilized CD16 and IL15 Expression to Enhance Directed Anti-Tumor Activity

Dan S Kaufman, MD PhD, Ryan Bjordahl, PhD, Huang Zhu, PhD, Robert Blum, Andres Bahena, Sajid Mahmood, PhD, Greg Bonello, PhD, Tom Lee, PhD, Bruce Walcheck, PhD, Frank Cichocki, PhD, Jeffrey S. Miller, MD, Bahram Valamehr, PhD

Blood (2018) 132 (Supplement 1): 4541.

https://doi.org/10.1182/blood-2018-99-113701

Published: 2018

Journal Articles

Induced Pluripotent Stem Cell-Derived NK Cells Genetically Modified to Express NKG2C/DAP12 Mediate Potent Function When Targeted through an NKG2C/IL-15/CD33 Tri-Specific Killer Engager (TriKE)

Emily Chiu, PhD, Frank Cichocki, PhD, Martin Felices, PhD, Sarah Cooley, MD, Helen Chu, PhD, Moyar Q. Ge, PhD, Ryan Bjordahl, PhD, Dan S Kaufman, MD PhD, Karl-Johan Malmberg, MD PhD, Bahram Valamehr, PhD, Jeffrey S. Miller, MD

Blood (2018) 132 (Supplement 1): 729.

https://doi.org/10.1182/blood-2018-99-112202

Published: 2018

Journal Articles

Adaptive NK Cells Are Expanded By NKG2C-Agonist Antibodies and Retain Their Cytotoxic and Secretory Properties

Aimee Merino, MD PhD, Phillip Dougherty, BS, Bin Zhang, PhD, J.P. Houchins, PhD, Jeffrey S. Miller, MD, Frank Cichocki, PhD

Blood (2018) 132 (Supplement 1): 3695.

https://doi.org/10.1182/blood-2018-99-113669

Published: 2018

Journal Articles

Development and Scale-up of a Novel GMP Method for Enrichment and Expansion of Terminally Differentiated Adaptive Natural Killer Cells (FATE-NK100) with Enhanced Anti-Tumor Function

Frank Cichocki, PhD, Bahram Valamehr, PhD MBA, Dhifaf Sarhan, PhD, Bin Zhang, Sarah Cooley, MD, Michael R. Verneris, MD, Bruce R. Blazar, MD, Ryan Bjordahl, PhD, Betsy Rezner, BS, Paul Rogers, PhD, Chad Green, David H McKenna, MD, Daniel Shoemaker, PhD, Scott Wolchko, MS, Jeffrey S. Miller, MD

Blood (2016) 128 (22): 1225.

https://doi.org/10.1182/blood.V128.22.1225.1225

Published: 2016

Journal Articles

Adaptive NK Cell Expansion Is Associated with Reduced Relapse of Lymphoid Malignancies after Autologous Hematopoietic Cell Transplant

Rohtesh S. Mehta, MD MPH, MS, Rose Wangen, Frank Cichocki, PhD, Martin Felices, PhD, Xianghua Luo, PhD, Daniel J. Weisdorf, MD, Michael R. Verneris, MD, Jeffrey S. Miller, MD, Sarah Cooley, MD

Blood (2016) 128 (22): 515.

https://doi.org/10.1182/blood.V128.22.515.515

Published: 2016

Journal Articles

Mast Cell Regulatory Gene Variants Are Common in Mast Cell Activation Syndrome

Lawrence B Afrin, MD, Frank Cichocki, PhD, Andrea Hoeschen, M.A., Kenneth B Beckman, PhD, Kalpna Gupta, PhD, Julia Nguyen, BS, Kevin A Silverstein, PhD, Lauren J Mills, PhD

Blood (2016) 128 (22): 4878.

https://doi.org/10.1182/blood.V128.22.4878.4878

Published: 2016

Journal Articles

CMV Reactivation is Associated with Reduced Relapse Risk, Better Disease-Free Survival and Expansion of Adaptive NK Cells after Reduced Intensity Hematopoietic Cell Transplantation

Frank Cichocki, PhD, Zachary B. Davis, PhD, Todd E. DeFor, MS, Sarah A. Cooley, MD MS, Yenan T. Bryceson, PhD, Don J. Diamond, PhD, Bruce R. Blazar, MD, Claudio Brunstein, MD, John E. Wagner, MD, Michael R. Verneris, MD, Daniel J. Weisdorf, MD, Jeffrey S. Miller, MD

Blood (2014) 124 (21): 668.

https://doi.org/10.1182/blood.V124.21.668.668

Published: 2014

Journal Articles

Clonal Expansion of Adaptive NK Cells and NKG2C + CD57 + KIR-Expressing T Cells from Sibling, but Not Umbilical Cord Blood, Grafts Is Induced By Recipient Latent CMV and Is Associated with Protection Against CMV Reactivation

Zachary B. Davis, PhD, Frank Cichocki, PhD, Martin Felices, PhD, Rose Wangen, Todd E. DeFor, MS, Sarah A. Cooley, MD MS, Yenan T. Bryceson, PhD, Don J. Diamond, PhD, Claudio Brunstein, MD, Bruce R. Blazar, MD, John E. Wagner, MD, Daniel J. Weisdorf, MD, Amir Horowitz, Lisbeth A Guethlein, Peter Parham, PhD, Michael R. Verneris, MD, Jeffrey S. Miller, MD

Blood (2014) 124 (21): 181.

https://doi.org/10.1182/blood.V124.21.181.181

Published: 2014

NARROW

Triple Gene-Modified iPSC-Derived NK Cells Combined with Daratumumab for Targeted Immunotherapy Against AML

FT576: Multi-Specific Off-the-Shelf CAR-NK Cell Therapy Engineered for Enhanced Persistence, Avoidance of Self-Fratricide and Optimized Mab Combination Therapy to Prevent Antigenic Escape and Elicit a Deep and Durable Response in Multiple Myeloma

CAR19 iPSC-Derived NK Cells Utilize the Innate Functional Potential Mediated through NKG2A-Driven Education and Override the HLA-E Check Point to Effectively Target B Cell Lymphoma

iPSC-Derived NK Cells Synergize with T Cells and Anti-PD-1 Antibody to Mediate Durable Anti-Tumor Responses In Vivo

FT538: Preclinical Development of an Off-the-Shelf Adoptive NK Cell Immunotherapy with Targeted Disruption of CD38 to Prevent Anti-CD38 Antibody-Mediated Fratricide and Enhance ADCC in Multiple Myeloma When Combined with Daratumumab

FT596: Translation of First-of-Kind Multi-Antigen Targeted Off-the-Shelf CAR-NK Cell with Engineered Persistence for the Treatment of B Cell Malignancies

NK Cells Lacking CD38 Are Resistant to Oxidative Stress-Induced Death

CD38-Deficient, CD16-Engineered NK Cells Exhibit Enhanced Antibody-Dependent Cellular Cytotoxicity without NK Cell Fratricide to Augment Anti-Myeloma Immunity in Combination with Daratumumab

iPSC-Derived NK Cells and Anti-PD-1 Antibody Synergize to Enhance T Cell Cytokine and Cytolytic Responses Against Multiple Tumors

Off-the-Shelf Natural Killer Cells with Multi-Functional Engineering Using a Novel Anti-CD19 Chimeric Antigen Receptor Combined with Stabilized CD16 and IL15 Expression to Enhance Directed Anti-Tumor Activity

Induced Pluripotent Stem Cell-Derived NK Cells Genetically Modified to Express NKG2C/DAP12 Mediate Potent Function When Targeted through an NKG2C/IL-15/CD33 Tri-Specific Killer Engager (TriKE)

Adaptive NK Cells Are Expanded By NKG2C-Agonist Antibodies and Retain Their Cytotoxic and Secretory Properties

Development and Scale-up of a Novel GMP Method for Enrichment and Expansion of Terminally Differentiated Adaptive Natural Killer Cells (FATE-NK100) with Enhanced Anti-Tumor Function

Adaptive NK Cell Expansion Is Associated with Reduced Relapse of Lymphoid Malignancies after Autologous Hematopoietic Cell Transplant

Mast Cell Regulatory Gene Variants Are Common in Mast Cell Activation Syndrome

CMV Reactivation is Associated with Reduced Relapse Risk, Better Disease-Free Survival and Expansion of Adaptive NK Cells after Reduced Intensity Hematopoietic Cell Transplantation

Clonal Expansion of Adaptive NK Cells and NKG2C + CD57 + KIR-Expressing T Cells from Sibling, but Not Umbilical Cord Blood, Grafts Is Induced By Recipient Latent CMV and Is Associated with Protection Against CMV Reactivation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only